Abstracts Archive - Page 358 of 2607 - ACR Meeting Abstracts

Abstract Number: 0754 • ACR Convergence 2024
Clinical Characterization of Aortitis and Periaortitis in a Cohort of 134 Patients from a Single Universitary Center. A Model-based Cluster Analysis
Carmen Secada Gómez¹, Javier Loricera², Adrián Martín-Gutiérrez³, Fernando Lopez-Gutierrez⁴, María Nuñez-Sayar⁵, Ander Ucelay-Aristi⁵, Isabel Martinez-Rodriguez⁶, ivan Ferraz-Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco-Alonso⁹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁵Cardiovascular Surgery, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Aortitis and periaortitis represent the inflammation of the aortic wall and the surrounding periaortic tissues, respectively. Both can be idiopathic or secondary to infectious…
Abstract Number: 0687 • ACR Convergence 2024
Patterns of Disease Progression in Early Systemic Sclerosis Patients with Interstitial Lung Disease
Lorenzo Beretta¹, Alessandro Santaniello², Silvia Bosello³, Enrico De Lorenzis⁴, Gerlando Natalello⁵, Nicoletta Del Papa⁶, Silvia Cavalli⁷, Devis Benfaremo⁸, Giacomo De Luca⁹, Corrado Campochiaro¹⁰, Lorenzo Cavagna¹¹, Veronica Codullo¹², Francesco Bonomi¹³, gaia Montanelli¹⁴, Adriana Severino¹⁵, Monica Caronni², Barbara Vigone², Silvia Bellando-Randone¹⁶, Carlomaurizio Montecucco¹⁷, Marco Matucci-Cerinic¹⁸, Lorenzo Dagna¹⁹, Gianluca Moroncini⁸, Roberto Caporali²⁰ and Chiara Bellocchi²¹, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, MILANO, Italy, ³FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI- IRCCS, Rome, Rome, Italy, ⁴Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁶ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Milan, Italy, ⁷University of Milan, Milan, Milan, Italy, ⁸Marche Polytechnic University, Ancona, Italy, ⁹Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁰IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹¹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ¹²Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ¹³Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Milan, Italy, ¹⁶University of Florence, Florence, Florence, Italy, ¹⁷IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ¹⁸University San Raffaele Milano, Milano, Milan, Italy, ¹⁹Ospedale San Raffaele, Milano, Italy, ²⁰Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²¹Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
Background/Purpose: Understanding the trajectory of disease progression in SSc-ILD is crucial for effective patient management and prognostication. Trajectory modeling offers a novel approach to deciphering…
Abstract Number: 0749 • ACR Convergence 2024
Age at Disease Onset Influences the Clinical Phenotype and Outcome of Patients with Takayasu Arteritis: Results from a Monocentric Cohort of 167 Patients
Alessandro Tomelleri¹, Corrado Campochiaro², Elena Baldissera³, Nicola Farina⁴, Marco Matucci-Cerinic⁵ and Lorenzo Dagna⁶, ¹Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³IRCCS San Raffaele Hospital, Milan, Italy, ⁴Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milan, Italy, ⁵University San Raffaele Milano, Milano, Milan, Italy, ⁶Ospedale San Raffaele, Milano, Italy
Background/Purpose: Takayasu arteritis (TAK) typically affects people between the ages of 20 and 40. However, disease onset can span across different age periods. Aim of…
Abstract Number: 0730 • ACR Convergence 2024
Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes
Michele Moretti¹, Elena Elefante², Francesco Ferro³, Ludovica Pisapia⁴, Federica Di Cianni⁵, Nazzareno Italiano⁶, ROSARIA TALARICO⁵, Chiara Baldini⁷ and Marta Mosca⁷, ¹University of Pisa, Pisa, Pisa, Italy, ²Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁵University of Pisa, Pisa, Italy, ⁶University of Pisa, Rovigo, Italy, ⁷University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: ANCA-associated vasculitides (AAVs) are characterized by severe and multisystemic manifestations that greatly affect patients' quality of life (QoL). The purpose of the study was…
Abstract Number: 0759 • ACR Convergence 2024
Macrophage-Lineage Cells in Giant Cell Arteritis Express MMP12, Phagocytosis and Osteoclast-associated Molecules That May Contribute to Destruction of the Tunica Media
Makoto Sugihara¹, Nobumasa Watanabe², Yuichiro Hara², Yasumasa Nishito³, Mai Kounoe⁴, Kazunari Sekiyama⁴, Eisuke Takamasu⁵, Naofumi Chinen⁶, Kota Shimada⁵ and Hideya Kawaji², ¹Department of Rheumatic Diseases, Tokyo Metropolitan Tama-Hokubu Medical Center, Tokyo, Japan, Higashimurayama-shi, Tokyo, Japan, ²Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ³Center for Basic Technology Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ⁴Center for Medical Research Cooperation, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ⁵Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, Fuchu-shi, Tokyo, Japan, ⁶Department of Rheumatic Diseases, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, Tokyo, Japan, Tama-shi, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis characterized by inflammatory cell infiltration and destruction of the tunica media. In this study, we…
Abstract Number: 0528 • ACR Convergence 2024
Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort
Sandra Carrillo¹, Daniel Xibille², Martha Mariana Castañeda-Martínez³, Alfredo Reyes⁴, Brian garcia-Arellano⁵, Edgar Vega Chávez⁶, Carlos vidal Montiel Castañeda⁵, Gabriel Carmona Lara⁶ and Gilberto De Hoyos⁵, ¹Hospital Angeles Lindavista, Mexico City, Distrito Federal, Mexico, ²Servicios de Salud de Morelos, Cuernavaca, Morelos, Mexico, ³ISSSTE, Monterrey, Mexico, ⁴ISSSTE, Ciudad de México, Mexico, ⁵ISSSTE, Ciudad de México, Distrito Federal, Mexico, ⁶ISSSTE, Ciudad de mexico, Distrito Federal, Mexico
Background/Purpose: Biological agents such as the TNF-α inhibitors have had a positive impact on the treatment of many chronic autoimmune diseases (AIDs), such as Rheumatoid…
Abstract Number: 0764 • ACR Convergence 2024
Primary Treatment Failure to Tocilizumab in Giant Cell Arteritis
Paul Cioni¹, Hubert de Boysson², Simon Parreau³, Perrine SMETS⁴, Maxime SAMSON⁵, Sara Melboucy⁶, Herve Lobbes⁷, Nabil Belfeki⁸, François Perrin⁹, Pascal Maurice Rossi¹⁰, Eric Liozon¹¹, Guillaume Le Guenno¹², Claire Le Jeunne¹, OLIVIER FOGEL¹³, Lola Prat¹⁴, Florent Ladouce¹⁵, Sylvie Grosleron¹⁶, Halil Yildiz¹⁷, Vincent Grosbost¹⁵, Xavier Puéchal¹⁸, Chloe Comarmond¹⁹ and Benjamin Terrier²⁰, ¹Cochin University Hospital, Paris, France, ²Caen university Hospital, Caen, France, ³Dupuytren hospital, Limoges, France, ⁴Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁵Dijon University Hospital, Dijon, France, ⁶CH Saint Quentin, Saint Quentin, France, ⁷CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸GHSIF - Melun, Melun, France, ⁹CH Saint Nazaire, Saint Nazaire, France, ¹⁰CHU Hopital Nord Marseille, Marseille, France, ¹¹CHU Limoges, Limoges, France, ¹²CHU, Clermont-Ferrand, France,, Clermont-Ferrand, France, ¹³AP-HP, Paris, France, ¹⁴Jacques Cartier Hospital, Massy, France, ¹⁵Clermont Ferrand University Hospital, Clermont Ferrand, France, ¹⁶CH Agen-Nerac, Agen, France, ¹⁷Saint-Luc University Clinic, Bruxells, Belgium, ¹⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁹Lariboisière University Hospital, Paris, France, ²⁰Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over the age of 50. Glucocorticoids are the cornerstone of treatment for GCA,…
Abstract Number: 0367 • ACR Convergence 2024
Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease
Peri Newman¹, Sharon Banks¹, Rayford June², Erik Lehman³, Glennys Smith⁴, Vandana Rai⁴, Nicole Wilson⁴, Nancy Olsen⁵ and Tarun Sharma⁴, ¹Penn State Health, Hershey, PA, ²Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ³Penn State College of Medicine, Hershey, PA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: The 2021 American College of Rheumatology guidelines for treatment of rheumatoid arthritis (RA) conditionally recommend a gradual discontinuation of methotrexate (MTX) over biologic discontinuation.…
Abstract Number: 0545 • ACR Convergence 2024
Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
Stylianos Georgiadis¹, Marion Pons², Simon Horskjær Rasmussen², Merete Hetland³, Louise Linde², Daniela DiGuiseppe⁴, Brigitte Michelsen⁵, Johan Karlsson Wallman⁶, Tor Olofsson⁷, Karel Pavelka⁸, Jakub Závada⁸, Bente Glintborg⁹, Anne Gitte Loft¹⁰, Catalin Codreanu¹¹, Daniel Melim¹², Diogo Esperança Almeida¹³, Tore K. Kvien¹⁴, Vappu Rantalaiho¹⁵, Ritva Peltomaa¹⁶, Bjorn Gudbjornsson¹⁷, Olafur Palsson¹⁸, Ovidiu Rotariu¹⁹, Ross MacDonald¹⁹, Ziga Rotar²⁰, Katja Perdan-Pikmajer²⁰, Karin Laas²¹, Florenzo Iannone²², Adrian Ciurea²³, Mikkel Ostergaard²⁴ and Lykke Oernbjerg¹, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Glostrup, Denmark, ³Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁴Karolinska Institutet, Stockholm, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ⁷Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁸Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁹DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁰Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹¹University of Medicine and Pharmacy, Bucharest, Romania, ¹²Hospital Egas Moniz, Lisbon, Portugal, ¹³Hospital de Braga, Braga, Portugal, ¹⁴Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁵Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ¹⁶Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ¹⁷Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁸University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁹University of Aberdeen, Aberdeen, United Kingdom, ²⁰University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ²¹East-Tallinn Central Hospital, Tallinn, Estonia, ²²Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²³University Hospital Zurich, Zürich, Switzerland, ²⁴Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: In observational studies, several longitudinal methods have been proposed to impute missing data of an individual by using the available information of the same…
Abstract Number: 0679 • ACR Convergence 2024
Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study
Rachel Wallwork¹, Haomin Hu², Ami Shah³, Laura Hummers⁴, John Pauling⁵, Victoria Flower⁶, Bambang Parmanto², Andi Saptono² and Robyn Domsic⁷, ¹Johns Hopkins University, Towson, MD, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene. Despite…
Abstract Number: 0365 • ACR Convergence 2024
Patients’ Behaviors and Beliefs Around Dietary Changes Among a Cohort of Patients with Rheumatic Disease
Aaron Stubbs, Deeba Minhas, Anne Arewasikporn and Andrew Schrepf, University of Michigan, Ann Arbor, MI
Background/Purpose: Dietary interventions may help manage inflammation and are considered for adjunctive treatment of rheumatic diseases. Our study aimed to explore patients' behaviors and beliefs…
Abstract Number: 0739 • ACR Convergence 2024
One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic
Patricia Harkins¹, Sharon Cowley², Robert Harrington³, seoidin McKittrick⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³St. James's Hospital, Dublin, Dublin, Ireland, ⁴University of Limerick, Limerick, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: To date the longitudinal outcomes of those with isolated Polymyalgia Rheumatica (PMR) are poorly understood, owing largely to the fact that in the majority…
Abstract Number: 0758 • ACR Convergence 2024
Difficult to Treat Takayasu Arteritis: Comparative Efficacy of Colchicine and Tofacitinib
Ravi Kumar¹, Prabhu Vasanth², Ramya Janardhana³, Arvind Ganapati⁴, Abhishek Patil⁵, Avinash Jain⁶, Benzeeta Pinto⁷, Ramesh Jois⁸, Shivraj Padiyar⁹, John Mathew⁹, Vineeta Shobha³, George Joseph² and Ruchika goel⁹, ¹Christian Medical college , Vellore , India, Bangalore, India, ²Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ³St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁴Kasturba Medical College, Rheumatology Division, Manipal , India, Vellore, Tamil Nadu, India, ⁵Manipal Hospital, Rheumatology, Bengaluru, India, Bengaluru, India, ⁶SMS Medical College and Hospital, Jaipur ,India, JAIPUR, India, ⁷St. John’s Medical College, Bengaluru , India, Bengaluru, India, ⁸Manipal Hospital ,Rheumatology, Millers Road, Bengaluru, India, Bengaluru, India, ⁹Christian Medical college , Vellore , India, Vellore, India
Background/Purpose: Biologic DMARDs (bDMARDs) are mainstay in management of patients with difficult to treat Takayasu Arteritis (D2TTAK). The cost of long-term biologics is prohibitory in…
Abstract Number: 0766 • ACR Convergence 2024
Neutrophil Transcriptomics in VEXAS Syndrome
Chloe Palmer¹, Gustaf Wigerblad¹, Tom Hill², Bhavisha Patel³, Emma Groarke⁴, Neal Young⁴, Stefania Dell'Orso⁵ and Peter Grayson⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ³National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations of the ubiquitin-like modifier activating enzyme 1 (UBA1) gene and…
Abstract Number: 0668 • ACR Convergence 2024
There Are No Shortcuts: Electronic Health Record-Generated Tool Does Not Reflect Medication Adherence in Patients with SLEin Bronx, NY
Kiera Brennan¹, Kai Sun², Anitha Ramu¹, Juliann Allen¹, Justina Shafik¹ and Noa Schwartz³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Duke University, Durham, NC, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is associated with poor outcomes in SLE.1 Electronic Health Record (EHR) platforms collect data on patient medication access through dispensing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].